Literature DB >> 19647200

Liver resection for metastatic colorectal cancer in the presence of extrahepatic disease.

Darren R Carpizo1, Michael D'Angelica.   

Abstract

Early studies of liver resection for colorectal cancer metastases identified patients with concomitant extrahepatic disease as a group with poor outcomes. These studies concluded that the presence of extrahepatic disease should be a contraindication to resection. This contraindication has more recently been challenged. In this paper, we review the published work on metastatic colorectal cancer, pertaining to the role of surgery in patients with liver metastases and concomitant extrahepatic disease. 5-year survival after resection is worse in patients with extrahepatic disease than in patients with liver-only disease, but is similar to that seen in patients who underwent resection in the era before the use of modern chemotherapy. Recurrence occurs in most patients. There is a role for surgery in highly selected patients with single sites of extrahepatic disease, although expectations should be different than those of patients with liver-only metastases. Further studies are necessary to define the patient group best suited for resection of hepatic metastases with extrahepatic disease.

Entities:  

Mesh:

Year:  2009        PMID: 19647200     DOI: 10.1016/S1470-2045(09)70081-6

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  25 in total

1.  Liver resection for liver metastases from nondigestive endocrine cancer: extrahepatic disease burden defines outcome.

Authors:  Andreas Andreou; Antoine Brouquet; Kishore G S Bharathy; Nancy D Perrier; Eddie K Abdalla; Steven A Curley; Matthias Glanemann; Daniel Seehofer; Peter Neuhaus; Jean-Nicolas Vauthey; Thomas A Aloia
Journal:  Surgery       Date:  2012-02-04       Impact factor: 3.982

Review 2.  [Assessment of resectability of colorectal liver metastases and extended resection].

Authors:  U Settmacher; H Scheuerlein; F Rauchfuss
Journal:  Chirurg       Date:  2014-01       Impact factor: 0.955

3.  Yttrium-90 radioembolization in the management of liver tumors: expanding the global experience.

Authors:  Ahsun Riaz; Riad Salem
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03       Impact factor: 9.236

4.  Prognostic value of treatment-related factors in metastatic colorectal cancer using a stop-and-go strategy.

Authors:  C J S Kronborg; A R Jensen
Journal:  Int J Colorectal Dis       Date:  2014-07-27       Impact factor: 2.571

5.  Prognostic factors for overall survival in metastatic colorectal cancer using a stop-and-go FLIRI-based treatment strategy.

Authors:  Camilla S Kronborg; Anni R Jensen
Journal:  Int J Colorectal Dis       Date:  2015-05-23       Impact factor: 2.571

6.  Colorectal Cancer Liver Metastases and Concurrent Extrahepatic Disease Treated With Resection.

Authors:  Universe Leung; Mithat Gönen; Peter J Allen; T Peter Kingham; Ronald P DeMatteo; William R Jarnagin; Michael I D'Angelica
Journal:  Ann Surg       Date:  2017-01       Impact factor: 12.969

7.  Sinusoidal obstruction syndrome compromises liver regeneration in patients undergoing two-stage hepatectomy with portal vein embolization.

Authors:  Masato Narita; Elie Oussoultzoglou; Marie-Pierre Chenard; Edoardo Rosso; Selenia Casnedi; Patrick Pessaux; Philippe Bachellier; Daniel Jaeck
Journal:  Surg Today       Date:  2010-12-30       Impact factor: 2.549

Review 8.  [Surgery for metastases, anatomical and ethical limits. Special aspect: oligometastases].

Authors:  A Perrakis; T A Juratli; W Hohenberger; R S Croner; G Schackert
Journal:  Chirurg       Date:  2016-03       Impact factor: 0.955

9.  Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal and hepatic metastases: a case-control study.

Authors:  Frans F Duraj; Peter H Cashin
Journal:  J Gastrointest Oncol       Date:  2013-12

Review 10.  Role of surgery in colorectal cancer liver metastases.

Authors:  Özgür Akgül; Erdinç Çetinkaya; Şiyar Ersöz; Mesut Tez
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.